PTC THERAPEUTICS, INC.

(PTCT)
  Rapport
Temps Différé Nasdaq  -  22:00 01/07/2022
41.85 USD   +4.47%
23/06PTC THERAPEUTICS, INC. : RBC Capital Markets confirme sa recommandation neutre
ZM
21/06PTC Therapeutics affirme que l'essai de Translarna confirme les avantages du traitement ; les actions sont en hausse.
MT
09/06PTC Therapeutics, Inc. nomme Alethia Young à son conseil d'administration
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur PTC THERAPEUTICS, INC.
24/06PTC THERAPEUTICS, INC.(NASDAQGS : PTCT) added to Russell Small Cap Comp Value Index
24/06PTC THERAPEUTICS, INC.(NASDAQGS : PTCT) added to Russell 2500 Value Index
24/06PTC THERAPEUTICS, INC.(NASDAQGS : PTCT) added to Russell 3000E Value Index
24/06PTC THERAPEUTICS, INC.(NASDAQGS : PTCT) added to Russell 3000 Value Index
24/06PTC THERAPEUTICS, INC.(NASDAQGS : PTCT) added to Russell 2000 Value Index
21/06PTC Therapeutics Says Translarna Trial Confirms Treatment Benefits; Shares Rally
21/06PTC THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
21/06TRANSCRIPT : PTC Therapeutics, Inc. - Special Call
20/06PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna&t..
10/06PTC Therapeutics to Relocate Its Corporate Headquarters
09/06PTC THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters ..
09/06Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
09/06PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors
06/06PTC Therapeutics, Inc. - Preliminary Results Presented at ASCO Demonstrated Promising C..
06/06PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference
03/06PTC Therapeutics Reports Positive Preliminary Results From Study of Unesbulin to Treat ..
03/06PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Pro..
31/05PTC Therapeutics, Inc. - FDA Approves Label Extension for Evrysdi for Infants with Spin..
31/05PTC Therapeutics Says FDA Approves Neuromuscular Disease Drug for Infants in Label Exte..
31/05FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Unde..
31/05PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants w..
27/05PTC THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
23/05PTC Therapeutics Receives Positive CHMP Opinion for Upstaza for the Treatment of AADC D..
23/05TRANSCRIPT : PTC Therapeutics, Inc. - Special Call
20/05PTC Therapeutics Receives Positive EMA Panel Opinion for Upstaza to Treat Rare Genetic ..
20/05PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of..
20/05PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatme..
20/05PTC Therapeutics Gets CHMP Backing for Upstaza in AADC Deficiency
11/05TRANSCRIPT : PTC Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference..
03/05PTC THERAPEUTICS : Q1 Earnings Snapshot
03/05PTC THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and..
03/05TRANSCRIPT : PTC Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022
03/05PTC THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
03/05Earnings Flash (PTCT) PTC THERAPEUTICS Reports Q1 Revenue $148.7M, vs. Street Est of $1..
03/05PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Result..
03/05PTC Therapeutics, Inc. Provides Earnings Guidance for 2022
03/05PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
02/05PTC Therapeutics to Participate at Upcoming Investor Conferences
29/04PTC Therapeutics to Participate at Upcoming Investor Conferences
19/04PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Result..
14/04PTC Therapeutics Says CHMP Opinion on Its Gene Therapy Marketing Application Expected N..
14/04PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficie..
14/04PTC Therapeutics, Inc. Provides Update on EMA Regulatory Review Timeline For Its AADC D..
08/04PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
30/03PTC Therapeutics Launches PTC518 Phase 2 Huntington's Disease Trial
30/03PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PT..
30/03PTC Therapeutics, Inc. Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evalu..
17/03TRANSCRIPT : PTC Therapeutics, Inc. Presents at Barclays Global Healthcare Conference 2022..
14/03PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinica..
11/03PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinica..
23/02SECTOR UPDATE : Health Care Stocks Unable to Retain Midday Rise
23/02SECTOR UPDATE : Health Care
23/02PTC Therapeutics to Participate at Upcoming Investor Conferences
22/02PTC THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and..
22/02PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 20..
22/02TRANSCRIPT : PTC Therapeutics, Inc., Q4 2021 Earnings Call, Feb 22, 2022
22/02PTC THERAPEUTICS : Q4 Earnings Snapshot
22/02PTC THERAPEUTICS : Provides a Corporate Update and Reports Fourth Quarter and Full Year 20..
22/02PTC THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
22/02PTC Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2022
22/02PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2..
22/02Earnings Flash (PTCT) PTC THERAPEUTICS Reports Q4 Revenue $165.2M
22/02PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 3..
08/02PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Fi..
26/01PTC Therapeutics - FDA Grants Evrysdi Priority Review Based on Results from Treating Pr..
25/01PTC Therapeutics Gets FDA's Priority Review for Spinal Muscular Atrophy Drug Evrysdi
25/01FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infa..
25/01PTC Therapeutics, Inc. Announces FDA Grants Evrysdi® Priority Review Based on Results f..
19/01PTC Therapeutics Announces Launch of 8th Annual STRIVE Awards Program to Fund Initiativ..
18/01PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund In..
13/01PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/01PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program
13/01Epilepsy Pipeline, Emerging Therapies, Key Pharma Players, Clinical Trials, Growth Pros..
10/01PTC Therapeutics Posts Higher Preliminary 2021 Net Revenue; Issues 2022 Outlook
10/01TRANSCRIPT : PTC Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference..
1  2  3  4  5  6  7  8  9  10Suiv.